Journal of Korean Medical Science

Korean Acad Medical Sciences (대한의학회)
권호 표지
DOI QR코드

DOI QR Code

Antidepressant Prescription Patterns in Bipolar Disorder: a Nationwide, Register-based Study in Korea

  • Yoon, Woon (Department of Psychiatry, University of Ulsan College of Medicine, Asan Medical Center) ;
  • Shon, Seung-Hyun (Department of Psychiatry, University of Ulsan College of Medicine, Asan Medical Center) ;
  • Hong, Youjin (Department of Psychiatry, University of Ulsan College of Medicine, Gangneung Asan Medical Center) ;
  • Joo, Yeon Ho (Department of Psychiatry, University of Ulsan College of Medicine, Asan Medical Center) ;
  • Lee, Jung Sun (Department of Psychiatry, University of Ulsan College of Medicine, Asan Medical Center)
  • Received : 2018.03.13
  • Accepted : 2018.08.07
  • Published : 2018.11.12
⟨ Previous Next ⟩

Abstract

Background: The role of antidepressants (ADs) in bipolar disorder is long-standing controversial issue in psychiatry. Many clinicians have used ADs as a treatment for bipolar depression, and the selection of therapeutic agents is very diverse and inconsistent. This study aimed to examine recent AD prescription patterns for patients with bipolar disorder in Korea, using the nationwide, population-based data. Methods: This study utilized the Korean nationwide, whole population-based registry data of the year 2010, 2011, and 2013. All prescription data of the ADs, antipsychotics, and mood stabilizers of the sampled patients diagnosed with bipolar disorder (n = 2,022 [in 2010]; 2,038 [in 2011]; 2,626 [in 2013]) were analyzed for each year. Results: Annual prescription rate of ADs was 27.3%-33.6% in bipolar disorder, which was gradually increasing over the 3-year period. The combination pattern of ADs and antipsychotic drugs tended to increase over 3 years. The proportion of females and the prevalence of comorbid anxiety disorder were significantly higher in AD user group in all three years. Among individual ADs, escitalopram was prescribed most frequently, and fluoxetine and bupropion were prescribed to the next many patients. The mean duration of bipolar depressive episodes was 135.90-152.53 days, of which ADs were prescribed for 115.60-121.98 days. Conclusion: Our results show prescription rate of ADs in bipolar disorder was maintained at substantial level and increased in recent 3 years. More empirical data and evidence are needed to establish practical treatment consensuses.

Keywords

References

  1. Rosa AR, Reinares M, Michalak EE, Bonnin CM, Sole B, Franco C, et al. Functional impairment and disability across mood states in bipolar disorder. Value Health 2010;13(8):984-8. https://doi.org/10.1111/j.1524-4733.2010.00768.x
  2. Pacchiarotti I, Bond DJ, Baldessarini RJ, Nolen WA, Grunze H, Licht RW, et al. The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry 2013;170(11):1249-62. https://doi.org/10.1176/appi.ajp.2013.13020185
  3. Amit BH, Weizman A. Antidepressant treatment for acute bipolar depression: an update. Depress Res Treat 2012;2012:684725.
  4. Verdoux H, Begaud B. Pharmaco-epidemiology: what do (and don't) we know about utilisation and impact of psychotropic medications in real-life conditions? Br J Psychiatry 2004;185(2):93-4. https://doi.org/10.1192/bjp.185.2.93
  5. Baek JH, Ha K, Yatham LN, Chang JS, Ha TH, Jeon HJ, et al. Pattern of pharmacotherapy by episode types for patients with bipolar disorders and its concordance with treatment guidelines. J Clin Psychopharmacol 2014;34(5):577-87. https://doi.org/10.1097/JCP.0000000000000175
  6. Blanco C, Laje G, Olfson M, Marcus SC, Pincus HA. Trends in the treatment of bipolar disorder by outpatient psychiatrists. Am J Psychiatry 2002;159(6):1005-10. https://doi.org/10.1176/appi.ajp.159.6.1005
  7. Judd LL, Schettler PJ, Akiskal HS, Maser J, Coryell W, Solomon D, et al. Long-term symptomatic status of bipolar I vs. bipolar II disorders. Int J Neuropsychopharmacol 2003;6(2):127-37. https://doi.org/10.1017/S1461145703003341
  8. Altshuler LL, Gitlin MJ, Mintz J, Leight KL, Frye MA. Subsyndromal depression is associated with functional impairment in patients with bipolar disorder. J Clin Psychiatry 2002;63(9):807-11. https://doi.org/10.4088/JCP.v63n0910
  9. Valtonen HM, Suominen K, Haukka J, Mantere O, Leppamaki S, Arvilommi P, et al. Differences in incidence of suicide attempts during phases of bipolar I and II disorders. Bipolar Disord 2008;10(5):588-96. https://doi.org/10.1111/j.1399-5618.2007.00553.x
  10. Woo YS, Bahk WM, Lee JG, Jeong JH, Kim MD, Sohn IK, et al. Korean Medication Algorithm Project for Bipolar Disorder 2018 (KMAP-BP 2018): fourth revision. Clin Psychopharmacol Neurosci 2008;16(4):434-48. https://doi.org/10.9758/cpn.2018.16.4.434
  11. Kessing LV, Vradi E, Andersen PK. Nationwide and population-based prescription patterns in bipolar disorder. Bipolar Disord 2016;18(2):174-82. https://doi.org/10.1111/bdi.12371
  12. Simon NM, Otto MW, Wisniewski SR, Fossey M, Sagduyu K, Frank E, et al. Anxiety disorder comorbidity in bipolar disorder patients: data from the first 500 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry 2004;161(12):2222-9. https://doi.org/10.1176/appi.ajp.161.12.2222
  13. Schaffer A, Cairney J, Veldhuizen S, Cheung A, Levitt A. Comparison of antidepressant use between subjects with bipolar disorder and major depressive disorder with or without comorbid anxiety. J Clin Psychiatry 2007;68(11):1785-92. https://doi.org/10.4088/JCP.v68n1119
  14. Kim L, Kim JA, Kim S. A guide for the utilization of Health Insurance Review and Assessment Service National Patient Samples. Epidemiol Health 2014;36:e2014008.
  15. Health Insurance Review and Assessment Service. Health Insurance Review and Evaluation Institute patient sample information. https://www.data.go.kr/dataset/3074368/fileData.do?lang=en. Updated 2017. Accessed March 11, 2018.
  16. Joe S, Lee JS. Association between non-compliance with psychiatric treatment and non-psychiatric service utilization and costs in patients with schizophrenia and related disorders. BMC Psychiatry 2016;16(1):444. https://doi.org/10.1186/s12888-016-1156-3
  17. Park SC, Lee MS, Kang SG, Lee SH. Patterns of antipsychotic prescription to patients with schizophrenia in Korea: results from the health insurance review & assessment Service-National Patient Sample. J Korean Med Sci 2014;29(5):719-28. https://doi.org/10.3346/jkms.2014.29.5.719
  18. R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2017.
  19. Revolution Analytics, Weston S. Foreach: provides foreach looping construct for R. R package version 1.4.3. https://cran.r-project.org/src/contrib/Archive/foreach/. Updated 2015. Accessed October 18, 2018.
  20. Wickham H. The split-apply-combine strategy for data analysis. J Stat Softw 2011;40(1):1-29.
  21. Dowle M, Srinivasan A. Data.table: extension of 'data.frame'. https://cran.r-project.org/src/contrib/Archive/data.table/. Updated 2017. Accessed October 18, 2018.
  22. Microsoft Corporation, Weston S. doParallel: foreach parallel adaptor for the 'parallel' package. R package version 1.0.11. https://cran.r-project.org/src/contrib/Archive/doParallel/. Updated 2017. Accessed October 18, 2018.
  23. Haeberle A, Greil W, Russmann S, Grohmann R. Mono- and combination drug therapies in hospitalized patients with bipolar depression. Data from the European drug surveillance program AMSP. BMC Psychiatry 2012;12(1):153. https://doi.org/10.1186/1471-244X-12-153
  24. McGirr A, Vohringer PA, Ghaemi SN, Lam RW, Yatham LN. Safety and efficacy of adjunctive second-generation antidepressant therapy with a mood stabiliser or an atypical antipsychotic in acute bipolar depression: a systematic review and meta-analysis of randomised placebo-controlled trials. Lancet Psychiatry 2016;3(12):1138-46. https://doi.org/10.1016/S2215-0366(16)30264-4
  25. Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Bond DJ, Frey BN, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord 2018;20(2):97-170. https://doi.org/10.1111/bdi.12609
  26. Altshuler L, Suppes T, Black D, Nolen WA, Keck PE Jr, Frye MA, et al. Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1-year follow-up. Am J Psychiatry 2003;160(7):1252-62. https://doi.org/10.1176/appi.ajp.160.7.1252
  27. Joffe RT, MacQueen GM, Marriott M, Young LT. One-year outcome with antidepressant--treatment of bipolar depression. Acta Psychiatr Scand 2005;112(2):105-9. https://doi.org/10.1111/j.1600-0447.2005.00583.x
  28. Ghaemi SN, Ostacher MM, El-Mallakh RS, Borrelli D, Baldassano CF, Kelley ME, et al. Antidepressant discontinuation in bipolar depression: a Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) randomized clinical trial of long-term effectiveness and safety. J Clin Psychiatry 2010;71(4):372-80. https://doi.org/10.4088/JCP.08m04909gre
  29. Kang SH, Kim YJ, An H, Joo YH, Kim CY. Treatment response and duration of maintenance treatment with adjunctive antidepressants in bipolar depression: a retrospective chart review. Int J Psychiatry Clin Pract 2009;13(2):130-7. https://doi.org/10.1080/13651500802585772
  30. Henry C, Van den Bulke D, Bellivier F, Etain B, Rouillon F, Leboyer M. Anxiety disorders in 318 bipolar patients: prevalence and impact on illness severity and response to mood stabilizer. J Clin Psychiatry 2003;64(3):331-5. https://doi.org/10.4088/JCP.v64n0316
  31. Boylan KR, Bieling PJ, Marriott M, Begin H, Young LT, MacQueen GM. Impact of comorbid anxiety disorders on outcome in a cohort of patients with bipolar disorder. J Clin Psychiatry 2004;65(8):1106-13. https://doi.org/10.4088/JCP.v65n0813
  32. Arnold LM. Gender differences in bipolar disorder. Psychiatr Clin North Am 2003;26(3):595-620. https://doi.org/10.1016/S0193-953X(03)00036-4
  33. Dube S, Tollefson GD, Thase ME, Briggs SD, Van Campen LE, Case M, et al. Onset of antidepressant effect of olanzapine and olanzapine/fluoxetine combination in bipolar depression. Bipolar Disord 2007;9(6):618-27. https://doi.org/10.1111/j.1399-5618.2007.00491.x
  34. McElroy SL, Weisler RH, Chang W, Olausson B, Paulsson B, Brecher M, et al. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry 2010;71(2):163-74. https://doi.org/10.4088/JCP.08m04942gre
  35. Young AH, McElroy SL, Bauer M, Philips N, Chang W, Olausson B, et al. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry 2010;71(2):150-62. https://doi.org/10.4088/JCP.08m04995gre
  36. Young AH, McElroy SL, Olausson B, Paulsson B; Embolden I (D1447C00001); Embolden II (D1447C00134) Investigators. A randomised, placebo-controlled 52-week trial of continued quetiapine treatment in recently depressed patients with bipolar I and bipolar II disorder. World J Biol Psychiatry 2014;15(2):96-112. https://doi.org/10.3109/15622975.2012.665177
  37. Lindstrom L, Lindstrom E, Nilsson M, Hoistad M. Maintenance therapy with second generation antipsychotics for bipolar disorder - a systematic review and meta-analysis. J Affect Disord 2017;213:138-50. https://doi.org/10.1016/j.jad.2017.02.012
  38. Hansen RA, Gartlehner G, Lohr KN, Gaynes BN, Carey TS. Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Ann Intern Med 2005;143(6):415-26. https://doi.org/10.7326/0003-4819-143-6-200509200-00006
  39. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009;373(9665):746-58. https://doi.org/10.1016/S0140-6736(09)60046-5
  40. Taylor DM, Paton C, Kapur S. The Maudsley prescribing guidelines in psychiatry. 12th ed. Hoboken, NJ: Wiley-Blackwell; 2015.

Cited by

  1. Examining Patterns of Polypharmacy in Bipolar Disorder: Findings from the REAP-BD, Korea vol.16, pp.5, 2018, https://doi.org/10.30773/pi.2019.02.26.4
  2. Complex Combination Pharmacotherapy for Bipolar Disorder: Knowing When Less Is More or More Is Better vol.17, pp.3, 2018, https://doi.org/10.1176/appi.focus.20190008
  3. Comparison of serum protein profiles between major depressive disorder and bipolar disorder vol.20, pp.None, 2018, https://doi.org/10.1186/s12888-020-02540-0
  4. The effects of vagus nerve stimulation on the course and outcomes of patients with bipolar disorder in a treatment-resistant depressive episode: a 5-year prospective registry vol.8, pp.None, 2018, https://doi.org/10.1186/s40345-020-0178-4
  5. Current status and progress of electroencephalogram study in patients with bipolar disorder vol.111, pp.6, 2018, https://doi.org/10.23736/s0026-4806.19.06160-3
  6. Pre‐diagnostic and post‐diagnostic psychopharmacological treatment of 16 288 patients with bipolar disorder vol.23, pp.4, 2018, https://doi.org/10.1111/bdi.12976